MCL1 and metastatic malignant neoplasm in the lymph nodes: In patients with lymph node metastasis and with disease free survival time greater than or equal to 29 months (n=36), high MCL1 gain tended to associate with poorer DFS (P=0.007) and OS (P=0.029) (Figure 2 and 3) (Table 3).